Real-world study on the efficacy and safety of traditional Chinese medicine in treating patients infected with COVID-19

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300067484

Enrollment

Unknown

Registered

2023-01-09

Start date

2023-01-09

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients infected with COVID-19

Interventions

Experimental group(Mild):Routine basic treatment should be carried out in accordance with the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial 10th Edition) formulated by the Na

Experimental group(Moderate):Routine basic treatment should be carried out in accordance with the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial 10th Edition) formulated by th

Experimental group(Heavy):Routine basic treatment should be carried out in accordance with the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial 10th Edition) formulated by the N

Experimental group(Critical):Routine basic treatment should be carried out in accordance with the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial 10th Edition) formulated by th

Control group:The non-traditional Chinese medicine treatment group. The treatment should be carried out according to the actual clinical treatment needs without using of traditional Chinese medicine,

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age =18 years old, gender unlimited; (2) Meet the diagnostic criteria for novel coronavirus pneumonia in the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial 10th Edition); (3) Participate in the experiment voluntarily and sign a written informed consent.

Exclusion criteria

Exclusion criteria: (1) Women who are pregnant or planning to become pregnant, breastfeeding women, and patients of childbearing age who are unable or unwilling to take adequate contraception during the trial or whose spouse is unwilling to take contraceptive measures; (2) Patients who are allergic to intervention TCM ingredients; (3) Other conditions in which the researcher judges that the patient is not suitable to participate in the study according to the actual clinical situation.

Design outcomes

Secondary

Measure	Time frame
Turning more serious classification ratio(all types);hospital stays(Moderate, Heavy, Critical);Oxygen saturation of finger and arterial blood gas analysis during breathing at rest (Moderate, Heavy, Critical);Lung CT inflammatory absorption time(Moderate, Heavy, Critical);case fatality rate(Critical);	—

Primary

Measure	Time frame
Time of symptom resolution(all types);	—

Countries

China

Contacts

Public ContactYueqiu Gao

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

gaoyueqiu@hotmail.com13795388789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026